| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(8 years from now) | |
| US10434103 | TAIHO ONCOLOGY | Crystal of 3,5-disubstituted benzene alkynyl compound |
Mar, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833151 | TAIHO ONCOLOGY | Pharmaceutical composition including sodium alkyl sulfate |
Nov, 2039
(15 years from now) | |
Lytgobi is owned by Taiho Oncology.
Lytgobi contains Futibatinib.
Lytgobi has a total of 3 drug patents out of which 0 drug patents have expired.
Lytgobi was authorised for market use on 30 September, 2022.
Lytgobi is available in tablet;oral dosage forms.
Lytgobi can be used as method of treating intrahepatic cholangiocarcinoma.
Drug patent challenges can be filed against Lytgobi from 30 September, 2026.
The generics of Lytgobi are possible to be released after 05 November, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2027 |
| Orphan Drug Exclusivity(ODE-410) | Sep 30, 2029 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 30 September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Dosage: TABLET;ORAL
LYTGOBI family patents
